Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Litorina Kapital III L.P. on the acquisition of Securia
Mandate

Vinge advises Litorina Kapital III L.P. on the acquisition of Securia

July 02, 2007

Vinge advises Litorina Kapital III L.P. on the acquisition of Securia Systems AB from TCI UK Ltd. Securia provides securities and insurance related services mainly on the Swedish market. Through this acquisition, Litorina Kapital III L.P will become the majority shareholder in the company while the previous owners will hold a minority share.

Litorina Kapital III L.P. is represented by partners Johan Winnerblad and Mikael Ståhl, assisted by Anna Berntsson, Mi Gustavsson and Nils Taro-Lock.

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026